v3.26.1
Evaluation and Collaborative Arrangements (Additional Information) (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2025
Aug. 31, 2024
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Long-Term Purchase Commitment [Line Items]              
Cash and cash equivalents     $ 4,868 $ 10,216 $ 4,868 $ 10,216 $ 18,618
Accounts Receivable         0 (428)  
Accounts receivable     2,042   2,042   2,042
Deferred Revenue     5,123   5,123   8,539
Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Accounts receivable     2,000   2,000    
Up front payment arrangement         10,000    
Transaction price $ 10,000            
Chugai Pharmaceutical Company Limited [Member] | Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Cash received         8,000    
Up front payment arrangement             $ 10,000
Revenue from contract 10,000   1,700   3,400    
Target fees 5,000            
Deferred Revenue     5,100   5,100    
ProGen Company Limited [Member] | Collaboration Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Contra-research and development expense     100   400    
Research And Development Arrangement [Member]              
Long-Term Purchase Commitment [Line Items]              
Accounts Receivable   $ 600          
Up front payment arrangement   600          
Contract Revenue   $ 1,200          
Research And Development Arrangement [Member] | Chugai Pharmaceutical Company Limited [Member]              
Long-Term Purchase Commitment [Line Items]              
Revenue from contract       $ 0   $ 200  
Contract liability     $ 0   $ 0    
Development Milestones [Member] | Chugai Pharmaceutical Company Limited [Member] | Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Revenue Regulatory and Development Milestone Received 57,000            
Sales-based Milestones [Member] | Chugai Pharmaceutical Company Limited [Member] | Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Revenue from contract 100,000            
Customer's Option [Member] | Chugai Pharmaceutical Company Limited [Member] | Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Revenue Regulatory and Development Milestone Received 10,000            
Technology Transfer Milestones [Member] | Chugai Pharmaceutical Company Limited [Member] | Chugai Collaboration and License Agreement [Member]              
Long-Term Purchase Commitment [Line Items]              
Up front payment arrangement $ 18,000